Cabaret Biotech Files Lawsuit Against Gilead Over Yescarta Drug

Sept. 16, 2019, 8:45 PM

Closely held Cabaret Biotech said it had filed a preemptive lawsuit against Gilead Sciences Inc. and its Kite unit “to end a needless dispute about patent royalties” over the cancer treatment Yescarta.

  • Gilead, which exclusively licenses a patent from Cabaret for Yescarta in the field of oncology, has protested its royalty payment obligations since October 2018, according to complaint filed Monday in federal court in Wilmington, Delaware
  • Cabaret is seeking a judgment that the patent isn’t invalid and that but for the license agreement, Yescarta infringes the patent, complaint says
  • Kite paid licensing fees, royalties and milestone payments to Cabaret ...

To read the full article log in.

Learn more about A Bloomberg Law subscription.